Clinical Trial Success Uncertainty: Inmed's lead drug candidates are in various stages of clinical development, and there is no guarantee these trials will demonstrate sufficient safety and efficacy for regulatory approval, or that they won't face delays or outright failures.

Regulatory Approval Hurdles: Even with positive clinical trial data, obtaining marketing authorization from regulatory bodies like the FDA or EMA is a complex and lengthy process with no assured outcome, potentially delaying or preventing commercialization.

Future Funding Requirements: As a pre-revenue biopharmaceutical company, Inmed incurs significant R&D and operational expenses, necessitating substantial additional capital raises in the future, which could dilute existing shareholder ownership.